Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review

Clinical Infectious Diseases

Volumn 24, Issue 5, 1997, Pages 810-816

  Hatala, Rose ^a,b   Dinh, Tuan T ^a   Cook, Deborah J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZLOCILLIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; FLUCLOXACILLIN; NETILMICIN; PIPERACILLIN; TOBRAMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEVER; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; TREATMENT OUTCOME;

EID: 0030893853     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.5.810     Document Type: Article

References (18)

1. Klastersky J, Cappel R, Daneau D. Clinical significance of in vitro synergism between antibiotics in Gram-negative infections. Antimicrob Agents Chemother 1972;2:470-5.
2. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-8.
3. Rolston KUI, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
4. Hughes WT, Chairman, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
5. Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer 1993;29A(suppl 1):S6-10.
6. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 1991;164:907-16.
7. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
8. Parker SE, Davey PG. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1993;31:4-8.
9. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989;24:281-93.
10. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996;124:717-25.
11. Galøe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995;48:39-43.
12. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-44.
13. Talott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-14.
14. Anaissie EJ, Vadhan-Raj S. Is it time to redefine the management of febrile . neutropenia in cancer patients? [editorial]. Am J Med 1995;98:221-3.
15. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
16. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
17. Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 1993;58:63-72.
18. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993;31:585-98.